Using Tranexamic Acid to Reduce Bleeding During Colon Polyp Removal

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of tranexamic acid (TXA) in preventing bleeding during and after endoscopic mucosal resection (EMR) of large colon polyps. The research focuses on patients undergoing this procedure, which, while effective in reducing colon cancer incidence, carries risks of significant bleeding. By administering TXA locally, the investigators aim to minimize both intraprocedural and postprocedural bleeding, potentially improving patient outcomes and reducing the need for additional interventions. The study is being conducted at a tertiary academic center, ensuring a robust patient population and clinical oversight.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients referred for endoscopic resection of non-neoplastic and neoplastic lesions in the colon presenting to our tertiary academic center.
* Age \> 18 years

Exclusion Criteria:

* patients with histories of allergic reactions to TXA
* history of seizures
* pregnancy

Where it's running

• Shamir Medical Center
  Be’er Ya‘aqov, Israel Recruiting

Study contacts

• Principal investigator: Anton Bermont, MD — Assaf-Harofeh Medical Center
• Study coordinator: Anton Bermont, MD
• Email: bermont@doctor.com
• Phone: +972526944145

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Liquid biopsy and machine learning to detect early colorectal cancer, advanced adenomas, Lynch-related cancers, and residual disease

  This project will test a blood-based liquid biopsy that uses microRNA signals and machine learning to detect colorectal cancer, advanced adenomas, Lynch-associated cancers, and molecular residual disease in people who have a colonoscopy.

  Recruiting San Raffaele University · Milan, Lombardy and 3 other locations · NCT07450612

• Blood microRNA markers for chemotherapy-related peripheral nerve damage in lung and colorectal cancer

  This study will test whether levels of tiny blood molecules called microRNAs can predict how often and how badly patients with lung or colorectal cancer get nerve damage from certain chemotherapies.

  Recruiting University Hospital, Clermont-Ferrand · Clermont-Ferrand · NCT07427537

• Minimally invasive surgery for early-stage colon cancer

  This study is testing a new, less invasive surgery for early-stage colon cancer to see if it can lower the chances of cancer coming back compared to the standard surgery.

  Recruiting Meander Medical Center · Amersfoort · NCT06652672

• Combining chemotherapy and immunotherapy for advanced colon cancer

  This study is testing a new treatment that combines chemotherapy and immunotherapy to see if it can help people with advanced colon cancer shrink their tumors and live longer.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT05914389

• Using mesalamine to prevent colorectal cancer in Lynch Syndrome patients

  This study is testing if taking mesalamine can help prevent colorectal cancer in people with Lynch Syndrome.

  Recruiting at 5 sites Phase 2 Karolinska University Hospital · Aalborg and 7 other locations · NCT04920149

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.